CAR-T Spotlight

Delays Mean Some Miss Window for CAR T-Cell Therapy, Cardinal Health Data Show

January 25th 2021

Data gathered by Cardinal Health Specialty Solutions revealed roadblocks community oncology practices encounter when trying to navigate payer approvals for CAR T-cell therapy.

Moving a Step Closer to Using CAR T-Cell Therapy in Solid Tumors

December 28th 2020

A recent paper in Nature Cancer outlines a novel strategy for overcoming barriers to CAR T-cell therapy in glioblastoma by pretreating the vascular microenvironment.

Deepu Madduri, MD, Discusses CARTITUDE-1 Data for Multiple Myeloma—and Clinical Trials During COVID-19

December 18th 2020

At the recent meeting of the American Society of Hematology, results from several studies involved the use of chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma.

Real-World Data Offer Good News for CAR T-Cell Therapy

December 15th 2020

Karl Kilgore, PhD, a senior research scientist at Avalere Health, discusses Medicare data that offer insights on the overall costs of CAR T-cell therapy relative to transplants.

Tanya Siddiqi, MD, Discusses the Promise of Reduced Toxicity With Liso-Cel

November 24th 2020

City of Hope's Dr. Tanya Siddiqi offers an update on a new chimeric antigen receptor (CAR) T-cell therapy awaiting approval from the FDA.

Gaining Knowledge of CAR T-Cell Therapy, and CRS, Over Time

November 9th 2020

OneOncology’s Duncan Allen, MHA, Discusses Bringing CAR T-cell Therapy to the Community Setting

November 1st 2020

The vice president for Clinical Services at OneOncology describes challenges and opportunities for chimeric antigen receptor (CAR) T-cell therapy in the community practice setting.